Findings presented at 50th Annual Meeting of ASCO show aromatase inhibitor effective for premenopausal women when combined with ovarian function suppression.
Sandra Kear, OncLive
Advertisement
Articles by Sandra Kear, OncLive
Advertisement
Latest Updated Articles
Practice-Changing Data Revealed for Premenopausal HR+ Breast CancerPublished: June 3rd 2014 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
MFN, DTC, and the Policy Pressure Cooker: Reshaping the US Drug Market
2
Eli Lilly, Novo Nordisk Strike MFN Deals With Trump Administration to Lower GLP-1 Prices
3
Oral Semaglutide Shows Promise for Weight Loss and Cardiometabolic Health
4
FDA Approves Lumateperone With Antidepressant Use for Major Depressive Disorder
5
